GlassScriptPhysician profile
Richard Yakimo
NPI 1811417363
$9,652.93
in general payments reported to CMS, 2019-2025
34 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $996 · 2022: $2,349 · 2023: $2,596 · 2024: $1,485 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,299 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,299.18 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,593.90 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,165.56 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $778.09 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $759.98 | 2021-2025 | |
| Axsome Therapeutics, INC. | $604.32 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $599.52 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $571.99 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $524.93 | 2021-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $424.32 | 2021-2025 | Spravato, Invega Sustenna, Invega |
| Neurocrine Biosciences, INC. | $389.69 | 2021-2025 | Ingrezza, Ongentys |
| Sunovion Pharmaceuticals INC. | $354.56 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $314.76 | 2021-2025 | Trintellix |
| Corium, LLC | $282.14 | 2023-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $215.87 | 2024-2025 | Cobenfy |
| Biogen, INC. | $137.95 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $121.29 | 2023-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Idorsia Pharmaceuticals US INC | $119.13 | 2022-2023 | Quviviq |
| Acadia Pharmaceuticals INC | $95.35 | 2021-2025 | Nuplazid |
| Tris Pharma INC | $80.71 | 2024-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $69.92 | 2022-2023 | Belsomra |
| Bausch Health US, LLC | $66.19 | 2021-2022 | |
| Kyowa Kirin, INC. | $62.64 | 2023-2024 | Nourianz |
| Neos Therapeutics, LP | $57.58 | 2023 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $57.28 | 2021-2023 | Loreev Xr, Gralise |
| Ironshore Pharmaceuticals INC. | $42.12 | 2023-2024 | Jornay Pm |
| Eisai INC. | $30.46 | 2021-2024 | |
| Acorda Therapeutics, INC | $26.85 | 2023 | Inbrija, Ampyra |
| Grifols USA, LLC | $18.07 | 2024 | Gamunex-C |
| Collegium Pharmaceutical, INC. | $15.86 | 2025 | Jornay Pm |
| Novo Nordisk INC | $15.63 | 2023 | Wegovy |
| Tanabe Pharma America, INC. | $14.72 | 2023 | |
| Avanir Pharmaceuticals, INC. | $14.50 | 2022 | |
| Noven Therapeutics, LLC | $13.75 | 2025 | Xelstrym |
| Indivior INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Yakimo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.